SYN•X Pharma highlights strategic initiatives at AGM in Toronto, Canada, May 2, 2003
At its Annual General Meeting earlier this week, SYN•X Pharma Inc. revealed its strategy to drive revenues through product sales and alliances with multi-national life sciences companies.
The Company also outlined its commitment to strategically manage operational costs, in order to positively impact the bottom-line.
Rod Wilson, President and Chief Operating Officer told the audience that in the past, SYN•X had out-licensed its early technology, but that gave the company little control over the timing of revenues and royalties. "We are now in a position to commercialize our own products through manufacturing and co-distribution partnerships. This will provide our shareholders with greater certainty and value," he declared.
The key elements of the strategy are:
At the AGM, SYN•X outlined its "2002 Highlights" and recent developments, which include:
"The successes that SYN•X achieved over the past year have laid the foundation for an even more successful 2003. We have a rich pipeline of products, which we plan to rapidly bring to market, including our test for congestive heart failure that we will be launched in Europe later this year," commented Dr. George Jackowski, Chairman, CEO and Chief Scientific Officer.
Keywords : Toronto Ontario Canada SYN•X Pharma AGM Highlights Strategic initiative Proteomics Discovery Diagnostics Diabetes Alzheimer's Cardiovascular disease
| Download File | |
 | SynXPharma_AGM-Presentation.pps File Size : 795.648 |
